Should a med spa add a GLP-1 weight-loss program?

The real question is not whether GLP-1 pays, it is whether it fits you

Almost every aesthetic practice owner has now had the same conversation with themselves. Patients keep asking about semaglutide and tirzepatide, the clinic down the road has a program, and the recurring monthly revenue is tempting for a business that mostly lives on one-off treatments. The instinct is to run the numbers on whether a weight-loss program is profitable in the abstract. That is the wrong first question for a practice that already exists.

A GLP-1 program can be profitable in general and still be the wrong thing to bolt onto your med spa, because adding it is not a standalone decision. It competes for the same chairs, the same injector hours, the same front desk, and the same marketing dollars you are already using to sell neurotoxin and filler. The decision is not is this profitable. It is does this fit my patient base, and what does it do to the hours I already have. This post is about that add decision. For the underlying economics of the program itself, the pass-through drug cost and the recurring math, see are GLP-1 programs profitable and treat this as the layer on top of it.

Patient-base fit: the cross-sell is the whole case

The strongest argument for adding a weight-loss program to an aesthetic practice is not the program margin. It is that you already own the audience. Your existing patients skew toward people who spend out of pocket on how they look, who trust your clinical judgment, and who are already in your calendar every few months. That is a warmer, cheaper audience for a GLP-1 program than a cold market will ever be, and the reverse is also true: weight-loss patients coming in monthly are a captive audience for neurotoxin, skin, and body treatments they had not considered.

Before you get excited, be honest about the shape of your actual panel. The cross-sell only works if the two audiences overlap. A quick self-test:

• Demand signal. Are patients already asking, unprompted, about weight-loss options at aesthetic visits? Recurring, unsolicited questions are the cheapest market research you will ever get.
• Demographic overlap. Does your existing base match who seeks these programs, or would you be marketing to strangers with no relationship to your brand? If it is the latter, the acquisition cost looks a lot more like a cold start than a cross-sell.
• Brand permission. Do your patients see you as a place they would trust with a medical weight program, or strictly as a cosmetic injector? Adding a clinical service under a purely cosmetic brand is possible, but it is a repositioning, not a bolt-on.
• Retention lift. A monthly cadence gives you far more contact than a quarterly tox patient. Every one of those visits is a natural, low-pressure opening to book aesthetic work.

If the honest answer is that your patients are already asking and they look like weight-loss candidates, the cross-sell is real and the add is worth considering. If you would be marketing to strangers, you are not adding a service to a practice, you are starting a second business inside it.

Cannibalization: does the program steal your best hours?

Here is the risk owners almost always miss. A med spa does not have unlimited capacity. It has a finite number of injector hours, and those hours are already among the highest-earning in the building. The danger of a GLP-1 program is not that it loses money. It is that it quietly reallocates your scarcest, most valuable time toward lower-per-hour work, and your total profit falls even as your revenue climbs. That is the same trap behind revenue up, profit down: a bigger top line built on worse hours.

The way to see it clearly is the one metric that lets you compare completely different services on equal footing: profit per provider-hour. Whichever service earns more per hour of the same constrained provider has first claim on that provider's calendar. If a GLP-1 titration visit earns less per hour than a neurotoxin appointment, then every GLP-1 visit your injector runs is an hour not spent on your best work, and the program is cannibalizing, not adding.

A profit-per-provider-hour comparison, side by side

Work both with illustrative, conservative figures. Treat every number as a placeholder for your own; the point is the method, not the digits.

An injectable hour. Suppose a neurotoxin appointment takes about 30 minutes and the patient pays roughly $600. Product cost for that treatment runs illustratively around $240, leaving $360 of gross before labor. The injector's loaded cost is about $120 per hour, so 0.5 hours costs $60. Contribution for the appointment is $360 minus $60 = $300. Two of those fit in an hour, so the injectable hour contributes roughly $300 times 2 = $600 per provider-hour.

A GLP-1 hour. In steady state, a titration or maintenance visit runs about 15 minutes, so four fit in an hour. Suppose the program charges roughly $349 per month and the medication is a pass-through cost of about $200 (a volatile, moving number, treated only as a snapshot). That leaves $149 of gross before labor per member. The provider time for a 15-minute visit at $120 per hour costs $30, so the contribution attributable to that visit is $149 minus $30 = $119. Four visits in the hour give roughly $119 times 4 = $476 per provider-hour.

1. Injectable hour, illustrative: about $600 in contribution per provider-hour.
2. GLP-1 hour on the same injector, illustrative: about $476 in contribution per provider-hour.
3. Difference: roughly $124 per hour lost every time that injector runs a GLP-1 visit instead of neurotoxin. That is the cannibalization number, and it is invisible on a revenue report.

Two things follow. First, in this illustration the GLP-1 hour is genuinely good, $476 per hour is a number most services would envy. Second, it is still lower than the injectable hour, so running the program through your injector costs you money on the margin even though the program itself is profitable. The program is not the problem. Putting it on the wrong provider is. If you want the full method behind this comparison, see how to calculate profit per provider-hour.

Staffing and scope: who runs the recurring visits

The comparison above assumes the injector runs the GLP-1 visits. The entire add decision changes the moment you stop assuming that. The recurring nature of a weight-loss program, monthly check-ins that are largely dose management and monitoring, is exactly the kind of work that does not require your highest-earning aesthetic provider. If you can route it away from the injector, you protect the injectable hour and keep the program margin.

Think in three layers, and match each to the lowest appropriate-cost person within your scope and your state's supervision and prescribing rules, which vary and which you should confirm rather than assume:

• Oversight and intake. The prescribing decision, medical screening, and initial visit typically sit with an MD, NP, or PA depending on your structure and state. This is the most clinical layer and the one worth the senior time.
• Titration and maintenance. The recurring dose-step and tolerance visits are the bulk of the volume and the natural home for an RN or an NP under an appropriate protocol, not your injector. Moving these off the injector is the single lever that turns cannibalization into addition.
• Coordination. Refills, supply logistics, messaging, and scheduling are administrative labor. Systematize them and keep them off any clinical calendar entirely.

Rerun the earlier math with the maintenance visit on a provider whose loaded cost is $70 per hour instead of the injector's $120. A 15-minute visit now costs about $17.50 instead of $30, so per-visit contribution rises to $149 minus $17.50 = $131.50, and the GLP-1 hour earns roughly $131.50 times 4 = $526 per provider-hour. More importantly, that hour no longer competes with the $600 injectable hour at all, because it is a different person entirely. The program stops being a tax on your best hours and starts being genuinely additive capacity. Deciding whether that new person is a hire or a reallocation is its own question; see when to hire an associate provider.

Supply risk and the thin drug margin: two things to hedge

Two structural realities should shape how cautiously you enter, and neither is a reason to avoid the program so much as a reason to build it defensively.

Compounded-availability risk

Much of what made cash-pay GLP-1 programs scale was access to compounded semaglutide and tirzepatide at a lower per-dose cost than branded products. That access, its sourcing, and its pricing are volatile and depend on regulatory conditions that have shifted before and may shift again. It would be a mistake to build a program that only works at today's sourcing and today's price. Assume your drug cost can move against you, keep more than one sourcing path in mind, and price the program so it survives a change in what you can obtain and at what cost. Do not treat any current sourcing or regulatory situation as permanent.

The pass-through margin

The other reality is that most of what the patient pays is the medication, which is a pass-through cost, not your margin. The program earns on the recurring service wrapped around the dose, not the dose itself. That is covered in full in are GLP-1 programs profitable, so the one line to carry into the add decision is this: because the drug cost scales one-for-one with every patient, growth does not dilute your biggest cost the way it does for an injectable, and the only levers in your favor are the fee, the provider you assign, and how tight your overhead is.

Marketing and acquisition: warm cross-sell beats a cold start

The cheapest patients for a new program are the ones you already have. Lead with your existing base: a mention at aesthetic visits, an email to your patient list, a landing page for people who already know your name. Warm cross-sell converts at a fraction of the acquisition cost of paid advertising to strangers, and it is the difference between a program that is profitable from month one and one that spends its first year buying leads.

Be realistic about the flip side. If your base does not overlap and you have to acquire weight-loss patients cold, your acquisition cost climbs, and it eats directly into a margin that, after the pass-through drug cost, was already thin. That is precisely the case where the add looks like a good idea on paper and disappoints in practice. The cross-sell is not a nice-to-have in the business case; for most aesthetic practices it is the business case. To see where a new program should sit relative to the rest of your menu, use which cash-pay services make money and the add, keep, fix, or cut lens in is a service worth offering.

A clear framework: add, hold, or pass

Pull the threads together into a decision. None of these depends on the program being profitable in the abstract; they all turn on fit and on what the program does to the hours you already have.

Add

Your patients are already asking, the demographics overlap, and you can staff the recurring visits on someone other than your injector, an RN, NP, or PA within your scope and state rules. In this case the program is genuinely additive: it deepens retention, opens a monthly cross-sell channel, and earns a strong profit per provider-hour without touching your best injectable capacity. Price it as a program rather than a drug markup so it survives a change in sourcing, and go.

Hold

The fit is there but the capacity is not, meaning the only way to run the program today is through your injector. Do not launch into that. Solve the staffing first, hire or reallocate the person who will run titration, then add. Launching a fit-good, capacity-short program on your highest-earning provider is how you turn a good idea into the cannibalization the math above warned about.

Pass

Your base does not overlap, patients are not asking, and you would be marketing cold while your injector chairs sit less than full. Adding a GLP-1 program here does not add profit; it adds complexity, drug-supply risk, and acquisition cost to a practice whose real opportunity is filling the high-margin hours it already has. In that situation the better move is almost always to increase profit without more patients before adding a whole new service line.

See the decision on your own numbers

The honest version of this decision is impossible to make from a revenue report, because the whole risk, an injector hour quietly reallocated to lower-per-hour work, is invisible there. You have to see every service, and every provider, ranked by profit per provider-hour side by side.

The Inside Look walks through a sample aesthetic practice that looks healthy from the top, ranks each service by profit per provider-hour, and lets you add a GLP-1 program, assign it to a different provider, or change the cadence in an interactive forecaster and watch total profit move, so you can see the cannibalization or the addition before you commit a single chair. If you are weighing this add, start with why financial clarity is the difference between a program that funds your practice and one that just makes it busier, and read are GLP-1 programs profitable for the underlying economics this decision sits on top of.